AI eye exam could spot diabetes blindness before it starts

NCT ID NCT07378891

ENROLLING_BY_INVITATION Diagnosis Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether an artificial intelligence (AI) program can spot early signs of diabetic retinopathy—a condition that can lead to blindness—in people with prediabetes and diabetes. Researchers will take pictures of the retina and use the AI to analyze them. The goal is to see if this technology can catch eye damage earlier than current methods, potentially helping people get treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this could lead to a simple, AI-powered eye test that catches diabetes-related eye damage early, potentially preventing vision loss.
What could go wrong: This is a small, early-stage study (100 participants) focused on testing the AI's accuracy, not on treatment. The AI may not work as well in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES (DM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic retinopathy prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

DIABETES (DM) PREDIABETES

Contacts and locations

Locations

University Hospital Tuebingen, Dep. Diabetology

Tübingen, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.